Retatrutide: a triple incretin receptor agonist for obesity management.

Although the reductions in HbA1c and dose-dependent weight loss amongst individuals with T2DM were significantly more for higher-doses of retatrutide, it needs to be observed that the active comparator was dulaglutide, which is not approved for treatment of obesity, at a dose of 1.5 mg which is much lower than the highest approved dose of 4.5 mg. Dose-dependent increase in heart rate and incidents of mild to moderate cardiac arrythmias raise cardiovascular safety concerns and signify that carrying out long-term cardiovascular outcome trials (CVOTs) will be critical. Additionally, retatrutide's potential in heart failure management is intriguing given the series of positive findings of semaglutide on cardiovascular outcomes.